RA
ELOS

Royce & Associates’s Syneron Medical Ltd ELOS Stock Holding History

Royce & Associates’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-69,200
Closed -$758K – 1288
2017
Q2 		$758K Hold
69,200
– – 0.01% 1008
2017
Q1 		$730K Hold
69,200
– – ﹤0.01% 1015
2016
Q4 		$581K Sell
69,200
-351,459
-84% -$2.75M ﹤0.01% 999
2016
Q3 		$3.01M Sell
420,659
-367,500
-47% -$2.56M 0.02% 715
2016
Q2 		$6.06M Buy
788,159
+75,000
+11% +$535K 0.04% 528
2016
Q1 		$5.21M Buy
713,159
+50,000
+8% +$358K 0.03% 596
2015
Q4 		$5.11M Buy
663,159
+44,700
+7% +$341K 0.03% 613
2015
Q3 		$4.42M Buy
618,459
+180,900
+41% +$1.74M 0.02% 676
2015
Q2 		$4.65M Sell
437,559
-124,800
-22% -$1.46M 0.02% 752
2015
Q1 		$6.96M Sell
562,359
-319,400
-36% -$3.54M 0.03% 681
2014
Q4 		$8.23M Sell
881,759
-105,300
-11% -$1.02M 0.03% 658
2014
Q3 		$9.89M Hold
987,059
– – 0.03% 614
2014
Q2 		$10.2M Sell
987,059
-60,100
-6% -$650K 0.03% 657
2014
Q1 		$13M Sell
1,047,159
-143,900
-12% -$1.7M 0.04% 559
2013
Q4 		$14.7M Hold
1,191,059
– – 0.04% 519
2013
Q3 		$10.3M Hold
1,191,059
– – 0.03% 649
2013
Q2 		$10.4M Buy
+1,191,059
New +$10.6M 0.03% 609

Other funds holding ELOS

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Royce & Associates's ELOS Position: Q3 2017 in Review

Royce & Associates sold out of Syneron Medical Ltd (ELOS) in Q3 2017, closing a stake of 69,200 shares — an estimated $758K sold.

Royce & Associates first reported a position in ELOS in Q2 2013 and held it in 17 quarters. The position peaked at $14.7M in Q4 2013. 4 funds tracked by Wall St. Rank hold ELOS as of Q3 2017.

  • Royce & Associates reported no remaining Syneron Medical Ltd position as of Q3 2017 after selling out during the quarter.
  • Royce & Associates sold 69,200 Syneron Medical Ltd shares in Q3 2017, an estimated $758K.
  • Royce & Associates first reported a position in Syneron Medical Ltd in Q2 2013 and held it in 17 quarters.
  • Royce & Associates's Syneron Medical Ltd position peaked at $14.7M in Q4 2013.
  • 4 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q3 2017.

Based on Royce & Associates's 13F filing for Q3 2017, filed 13 Nov 2017.